In this FAQ Video Module, Claudia Rivera Salas, NP, a rheumatology nurse practitioner in East Lansing, Michigan, explains how clinicians choose between steroid-sparing agents for the treatment of polymyalgia rheumatica (PMR). She outlines when methotrexate may be used as a cost-effective option for patients with mild to moderate PMR, and when sarilumab (Kevzara), the only FDA-approved biologic for PMR, may be indicated in cases of moderate to severe disease, relapses, or steroid intolerance. Claudia reviews key differences in side effects, cost, onset of action, and clinical considerations, as well as highlights data from pivotal studies including the SAPHYR trial. This video offers valuable insights into optimizing PMR management, reducing long-term steroid use, and improving patient outcomes.

#PolymyalgiaRheumatica #PMR #Rheumatology #SteroidSparingAgents #Methotrexate #Sarilumab #PMRTreatment #AutoimmuneDisease #RheumatologyEducation